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GenoType MTBDRplus assayA B S T R A C T
Objective/Background: Multidrug-resistant tuberculosis (MDR-TB) is growing globally and
becoming a major challenge for national TB control programs. Therefore, rapid identifica-
tion of MDR strains of Mycobacterium tuberculosis and monitoring their transmission could
contribute significantly to the control of TB. The GenoType MTBDRplus assay has been rec-
ommended by the World Health Organization to identify rifampicin (RIF)- and isoniazid
(INH)-resistant M. tuberculosis isolates. This study was carried out to evaluate the perfor-
mance of the GenoType MTBDRplus assay for the detection of RIF- and INH-resistant
M. tuberculosis isolates in central Ethiopia.Methods: A total of 279M. tuberculosis strains isolated
from active TB cases in central Ethiopia were evaluated for their drug sensitivity by
the conventional drug-susceptibility test (DST) and compared with data derived from the
GenoType MTBDRplus assay. The DST served as the gold standard for evaluating the
GenoType MTBDRplus assay. Results: The sensitivity and specificity of the GenoType
MTBDRplus assay for the detection of RIF-resistant M. tuberculosis isolates were 80.0% and
99.6%, respectively. Its sensitivity and specificity for the detection of INH-resistantM. tuber-
culosis isolates were 82.7% and 99.6%, respectively, whereas they were 75.0% and 100%,
respectively, for the detection of MDR M. tuberculosis strains. The concordances of the
GenoType MTBDRplus assay and the conventional DST for the detection of RIF and INH sus-
ceptibility were 80% (8/10) and 86.2% (25/29), respectively. Furthermore, the concordance of
the two tests for the detection of MDR M. tuberculosis strains was 75%. Specific mutations
were detected in 55.6% (5/9) of the RIF-resistant isolates, with the highest mutation rate
(33.3%) for the rpoB gene (Codon S531L). For INH-resistant isolates, the highest mutation
476 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 4 7 5 –4 8 1rate (88.8%) related to a katGmutation (Codon S315T1). Conclusion: The findings of this study
revealed that the GenoType MTBDRplus assay has high sensitivity and specificity for the
detection of RIF and INH resistance. These preliminary data support the notion that the
assay should be considered as an alternative to the DST for the characterization of MDR
in M. tuberculosis isolates and the control of TB.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Tuberculosis (TB) is one of the major global health problems,
with high prevalence in developing countries. A major con-
cern is multidrug-resistant TB (MDR-TB), which is defined as
the resistance to isoniazid (INH) and rifampicin (RIF), two
therapeutic compounds for first-line TB treatment. The emer-
gence of strains resistant to major anti-TB drugs has
increased the need for identifying rapid and simple methods
to detect such resistances and their molecular basis in the
Mycobacterium tuberculosis genome. Using such tests promises
to improve the physician’s decision to appropriately treat the
disease in patients on an individual basis and allows better
monitoring of the emergence of MDR-TB strains in distinct
geographical regions, ultimately contributing to the preven-
tion of the spread of resistant strains. Drug-susceptibility
testing by conventional methods using solid media such as
Lo¨wenstein–Jensen is time consuming because M. tuberculosis
grows slowly in culture requiring several weeks to identify the
pathogen and test its drug-resistance profile. Even with more
automated fluid culture methods, the former method takes
an average of 14 days. Two additional weeks are required to
obtain information about the strain’s drug susceptibility [1].
Molecular methods for drug-resistance testing based on the
identification of mutations in genes associated with drug
resistance, such as the GenoType MTBDRplus assay, offer an
effective, alternative method to determine drug-resistance
strains [2]. The GenoType MTBDRplus assay is a
molecular-line probe assay containing probes specific for
the M. tuberculosis complex, wild type as well as probes for
common RIF- and INH-resistance-conferring mutations. The
assays are based on reverse hybridization of amplicons
immobilized on membranes. The GenoType MTBDRplus assay
detects mutations in the rpoB, katG, and inhA genes, and deliv-
ers results with a rapid turnaround time of 48–72 h. Nearly all
RIF-resistant strains contain mutations in the rpoB gene,
which encodes the RNA polymerase subunit b [3]. Mutations
in the katG and inhA genes are related to the high-level and
low-level INH resistance, respectively [3]. More than 95% of
the RIF-resistant strains harbor a mutation within an 81-bp
region of the rpoB gene from Codons 507 to 533 and this is
region is called the RIF resistance-determining region [4–6].
The highest level of RIF resistance of the rpoB gene occurs in
Codons 531 and 526. The rpoB gene mutations occur in
Codons 511, 516, 518, 522, and 533 and cause low-levelresistance to RIF. Resistance mutations are rarely identified
in other regions of the rpoB gene [4].
Mutations causing INH resistance are located in several
genes. Several studies have demonstrated that 34.6–94.3% of
INH resistance is most frequently associated with a mutation
in Codon 315 of the M. tuberculosis catalase peroxidase (katG)
gene [7,8]. The inhA gene has 2.9–21.5% of its mutations in
the promoter region [9], and an additional 2–11.5% in the
ahpC–oxyR intergenic region [10,11].
Ethiopia is one of the 27 high MDR-TB-burden countries in
the world. According to the 2015 World Health Organization
report, 1.6% of new TB patients and 12.0% of previously trea-
ted patients had MDR-TB [12]. Annually, 2000–2500 MDR-TB
cases are estimated to occur among all reported pulmonary
TB cases. However, for example, in the year 2012, only 212
(10.1%) TB cases were detected [13], indicating that the many
of the expected MDR-TB cases remain undiagnosed and con-
tinue to spread in various communities. Therefore, improved
monitoring of TB drug resistance—with respect to the time
required for detection of resistance and the sensitivity and
specificity of detection of MDR—is important, andmay benefit
from molecular tests such as the GenoType MTBDRplus assay.
The objective of this study was to evaluate the performance of
the GenoType MTBDRplus test in detecting INH- and
RIF-resistant M. tuberculosis isolates in central Ethiopia.
Materials and methods
M. Tuberculosis isolates
A total of 279 M. tuberculosis specimens isolated from smear-
positive TB patients who visited St. Lukas, Atat, and Fitche
hospitals in central Ethiopia between October 2012 and
September 2013 were used for this study. The study was eth-
ically approved by the Ethical Review Board of College of the
Natural Sciences of the Addis Ababa University, Ethiopia
(Ref. No. CNSDO/379/07/15).
Conventional drug-susceptibility testing using Lo¨wenstein–
Jensen media
The isolates were evaluated for their drug sensitivity using
the conventional proportion method and the sensitivity of
each isolate against the first-line drugs (INH, streptomycin,
RIF, and ethambutol) was evaluated by the indirect proportion
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international standard [14].
GenoType MTBDRplus assay
The GenoType MTBDRplus assay (Hain Lifescience, Nehren,
Germany) was performed according to the manufacturer’s
instructions [10]. The test is based on DNA strip technology
and has three steps: DNA extraction, multiplex polymerase
chain reaction (PCR) amplification, and reverse hybridization.
The assay screens for the absence and/or presence of wild-
type (WT) and/or mutant (MUT) DNA sequences within speci-
fic regions of three genes: the rpoB gene for RIF resistance, the
katG gene for high-level INH resistance, and the inhA gene for
low-level INH resistance. Each strip contains 27 reaction zones
and the results can be obtained within a day [11]. In brief, for
one PCR, 10 lL amplification mix A containing 10 buffer,
nucleotides, and DNA polymerase was mixed with 35 lL of
amplification mix B containing MgCl2, the biotinylated pri-
mers, and dye. Then, 5 lL of M. tuberculosis DNA was added
to the mixture, making the final volume of PCR mix to be
50 lL. The PCRs consisted of 15 min of denaturing at 95 C, fol-
lowed by 10 cycles of 30 s at 95 C and 120 s at 58 C, followed
by 20 additional cycles of 25 s at 95 C, 40 s at 53 C, and 40 s
at 70 C,with a final extension at 70 C for 8 min. For hybridiza-
tion, 20 lL of the amplification productsweremixedwith 20 lL
of the denaturing reagent (provided with the kit) and
denaturingwas performed for 5 min in each of the plasticwell.
Thereafter, 1 mL of prewarmed hybridization buffer was
added into each well and one strip was placed in each well.
The hybridization was performed at 45 C for 30 min, followed
by twowashing steps. For colorimetric detection of hybridized
amplicons, streptavidin conjugatedwith alkaline phosphatase
was added after which a substrate buffer was added. After
final washing, strips were air dried and fixed on paper. The
DNA of the standard strain H37Rv and molecular-grade water
were used as positive and negative controls, respectively.
Interpretation of results
Each strip consists of 27 reaction zones (bands) with six con-
trols including conjugate control (CC), amplification control
(AC), M. tuberculosis complex, rpoB locus control, katG locus
control, and inhA locus control. The remaining 21 reaction
zones are WT and mutation reaction zones including eight
rpoB WT and four MUT probes, one katG WT and two MUT
probes, and two inhAWT and four MUT probes. Results were
interpreted according to the manufacturer’s instructions [10].
In brief, the presence of CC bands indicates the efficiency of
the conjugate and substrate, the presence of AC bands indi-
cates the efficiency of DNA extraction and PCR procedures,
and the presence of the M. tuberculosis complex band indi-
cates that the tested bacterium belongs to the M. tuberculosis
complex. The three respective locus control bands (rpoB, katG,
and inhA) indicate the presence of the specific gene region.
The absence of the WT band is usually accompanied by the
presence of MUT, which indicates resistance and the presence
of all WT bands without the MUT band indicates susceptible
isolate. In rare cases, lack of WT band(s) without a corre-
sponding MUT band could be observed due to uncommonmutations in the probe region and the presence of both WT
and MUT bands in the same stripe might be an indication
for the presence of heteroresistance or mixed infection.
Results
Sensitivity and specificity of the GenoType MTBDRplus assay
for detection of RIF- and INH-resistant M. tuberculosis
Drug-sensitivity test was conducted on 279 M. tuberculosis
isolates using the GenoType MTBDRplus assay and the
Lo¨wenstein–Jensen medium-based proportion method. The
result of the GenoType MTBDRplus assay showed that most
isolates (96.8%) were susceptible to RIF; by contrast, suscep-
tibility to INH (91.0%) was lower than that of RIF (Table 1).
The GenoType MTBDRplus assay detected nine (3.2%) RIF-
resistant and 25 (9.0%) INH-resistant isolates. Moreover,
three (1.1%) isolates were found to be MDR by the GenoType
MTBDRplus assay.
The results of the evaluation of the performance of the
GenoType MTBDRplus assay in detecting drug resistance are
summarized in Table 2. The sensitivity and specificity of the
GenoType MTBDRplus assay for the detection of RIF-
resistantM. tuberculosis isolates were 80.0% and 99.6%, respec-
tively. Its sensitivity and specificity for detecting INH-
resistantM. tuberculosis isolates were 82.7% and 99.6%, respec-
tively, whereas they were 75.0% and 100%, respectively, for
detecting MDR M. tuberculosis strains. The concordances of
the GenoType MTBDRplus assay and the conventional DST
for the detection of RIF and INH susceptibility were 80%
(8/10) and 86.2% (25/29), respectively. Furthermore, the con-
cordance of the two tests in detecting MDR M. tuberculosis
strains was 75%.
Mutation patterns of RIF and INH produced by the GenoType
MTBDRplus assay
Specific mutation was detected in five of the nine RIF-
resistant isolates. Of these five, three isolates had mutation
at Codon S531L, whereas the remaining two isolates had
mutation at Codon H526D. In the remaining four RIF-
resistant isolates, WT8 probe was missing with no gain in
MUT3 probes and considered ‘‘unknown.”
In the GenoType MTBDRplus assay, INH resistance was
detected by using the probes of the katG and inhA genes. Of
the 25 INH-resistant isolates, katG mutation occurred in
88.0% (22/25) of the isolates and in all of these isolates, speci-
fic mutations were observed at Codon S315T1 of the katG
gene. Mutations in the inhA gene occurred only in three
INH-resistant isolates. Specific inhA mutations were observed
in two of the INH-resistant isolates, which had mutation at
Codon C15T, whereas in the remaining one isolate, the inhA
WT2 gene was missing without the presence of specific muta-
tion band. These isolates are also considered unknown
(Table 3).
Band patterns of drug-resistant M. tuberculosis strains
The genotypic profile of resistance to RIF and NIH was exam-
ined. Of the nine isolates that showed resistance to RIF by the
Table 2 – Performance of the GenoType MTBDRplus assay and the LJ medium-based proportion method as a gold standard for
the detection of resistance of Mycobacterium tuberculosis to rifampicin and isoniazid.
GenoType MTBDRplus assay LJ DST result
Resistance Susceptible Sensitivity Specificity PPV NPV
RIF Resistant 8 1 80 99.6 88.9 99.2
Susceptible 2 268
INH Resistant 24 1 82.7 99.6 96 98.4
Susceptible 5 249
MDR Resistant 3 0 75 100 100 99.6
Susceptible 1 275
DST, drug-susceptibility testing; INH, isoniazid; LJ, Lo¨wenstein–Jensen; MDR, multidrug resistance; NPV, negative predictive value; PPV, positive
predictive value; RIF, rifampicin.
Table 1 – Drug-susceptibility test result of the GenoType MTBDRplus assay (n = 279).
Drug-resistance pattern New cases n (%) Treated cases n (%)
RIF susceptible 260 (97.0) 10 (90.9)
INH susceptible 243 (90.6) 11 (100)
Only RIF resistance 5 (1.9) 1 (10.0)
Only INH resistance 22 (8.2) 0 (0.0)
Any RIF resistance 8 (3.0) 1 (10.0)
Any INH resistance 25 (9.3) 0 (0.0)
MDR (RIF + INH) resistance 3 (1.1) 0 (0.0)
INH, isoniazid; MDR-TB, multidrug-resistance tuberculosis; RIF, rifampicin.
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observed in two isolates, but missing of WT8 was observed
in seven isolates. MUT2A was observed in two RIF-resistant
isolates and MUT3 was observed in three RIF-resistant iso-
lates. In the remaining four isolates, WT8 was missing with-
out the corresponding mutation of MUT3.
Of the 25 INH-resistance isolates, 88% (22/25) isolates had a
high-level resistance profile to the drug, which indicated
absence of WT band WT1 and presence of corresponding
mutation bands of MUT1 in the katG gene. The remaining
three isolates showed a low-level resistance pattern; WT1
was missing in two isolates and WT2 was missing in one iso-
late of the inhA gene in INH resistance, and there was a corre-
sponding mutation in MUT1 in two isolates of the inhA
regulatory region (Fig. 1).
The band patterns of isolates resistant to RIF and INH
were observed in six of the RIF mono-resistant, 22 of the
INH mono-resistant, and three MDR isolates. In the rpoB
gene, the absence of WT5 was observed in two RIF mono-Table 3 – Mutation patterns of the GenoType MTBDRplus assay.
rpoB mutations Frequency katG mut
S531L 3 S315T1
H526Y 2 WT
UK (WT8 missed) 4 WT
RIF resistant 9
RIF susceptible 270
INH, isoniazid; RIF, rifampicin; UK, unknown mutation characterized b
mutation probes; WT, wild type.resistant isolates and there was a corresponding MUT2A in
these two RIF mono-resistant isolates. The absence of
WT8 was observed in four RIF mono-resistant isolates and
in all of the three MDR isolates. The corresponding MUT3
was observed in only one RIF mono-resistant and in two
MDR isolates. In the remaining four RIF-resistant isolates,
WT8 probe was missing with no gain in MUT3 probes
(Table 4).
In the case of INH-resistant strains, in the katG gene, the
missing WT1 was observed in 19/22 (86.4%) of the INH
mono-resistant isolates and in all of the three MDR isolates
(Table 4). The corresponding katG MUT1 was observed in all
of these 19 INH mono-resistant isolates and in all of the three
MDR isolates. In the case of the inhA gene, the absence of WT1
was observed in only two isolates and there was a presence of
the corresponding MUT1 in these two INH mono-resistant
isolates. In the same inhA gene, WT2 was missing in one
INH mono-resistant isolate without the presence of the corre-
sponding mutation gene.ations inhA mutations Frequency
WT 22
C15T 2
UK (WT2 missed) 1
INH resistance 25
INH susceptible 254
y no hybridization to one or more wild-type probes nor to any of
Fig. 1 – Representative DNA patterns obtained by the GenoType MTBDRplus assay. Lane 1, water as a negative control, Lanes
2, 3, 6, 8, 9, 10, 11, 12, 13, 14, and 15 all are examples of a pattern of RIFs and INHs; Lane 4, example of a pattern of RIFr and
INHr; Lane 5, example of a pattern of RIFs and INHr with katGmutation; Lane 7 is an example of a pattern of RIFs and INHr with
inhA mutation; Lane 16, H37Rv as a positive control. INH, isoniazid; RIF, rifampicin. Note: The superscript ‘r’ represent
resistance and ‘s’ represent sensitive.
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In this study, the performance of the GenoType MTBDRplus
assay for the detection of RIF- and or INH-resistant strains
ofM. tuberculosiswas evaluated on 279M. tuberculosis isolates,
which were isolated from pulmonary TB patients at three
towns and their surroundings in central Ethiopia. WeTable 4 – Band patterns of drug-resistant Mycobacterium tubercu
Gene Band Gene region/mutation RIF mono resista
n (%)
rpoB
WT1 506–509 6 (100)
WT2 510–513 6 (100)
WT3 513–517 6 (100)
WT4 516–519 6 (100)
WT5 518–522 4 (66.7)
WT6 521–525 6 (100)
WT7 526–529 6 (100)
WT8 530–533 2 (33.3)
MUT1 D516V 0 (0)
MUT2A H526Y 2 (33.3)
MUT2B H526D 0 (0)
MUT3 S531L 1 (16.7)
katG
WT1 315 6(100)
MUT1 S315T1 0 (0)
MUT2 S315T2 0 (0)
inhA
WT1 15/16 6 (100)
WT2 8 6 (100)
MUT1 C15T 0 (0)
MUT2 A16G 0 (0)
MUT3A T8C 0 (0)
MUT3B T8A 0 (0)
INH, isoniazid; MDR, multidrug resistant; MUT, mutation; RIF, rifampicinobserved that the GenoType MTBDRplus assay results had a
good concordance with the conventional DSTwith additional
advantage of a shorter turnaround time. The sensitivity and
specificity of the GenoType MTBDRplus assay for detection
of RIF- and INH-resistant M. tuberculosis isolates were very
good. The overall concordance of the GenoType MTBDRplus
assay and the conventional DST method was 88.5%. Thelosis strains using the GenoType MTBDRplus assay.
nce (N = 6) INH mono resistance (N = 22)
n (%)
MDR (N = 3)
22 (100) 3 (100)
22 (100) 3 (100)
22 (100) 3 (100)
22 (100) 3 (100)
22 (100) 3 (100)
22 (100) 3 (100)
22 (100) 3 (100)
22 (100) 0 (0)
0 (0) 0 (0)
0 (0) 0 (0)
0 (0) 0 (0)
0 (0) 2 (66.7)
3 (14.5) 0 (0)
19 (86.4) 3 (100)
0 (0) 0 (0)
20 (90.9) 3 (100)
21 (95.4) 3 (100)
2 (9) 0 (0)
0 (0) 0 (0)
0 (0) 0 (0)
0 (0) 0 (0)
; WT, wild type.
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were 80.0% and 99.6%, respectively, for the detection of RIF
resistance. Moreover, they were 82.7% and 99.6%, respectively,
for the detection of INH resistance. The result of another
study conducted in northwest Ethiopia reported sensitivity
and specificity of 92.0% and 99.0%, respectively, for the detec-
tion of INH resistance, whereas both sensitivity and speci-
ficity for the detection of RIF resistance were 100% [15]. A
study in India reported sensitivity, specificity, positive predic-
tive value, and negative predictive value of 97.6%, 94.4%,
97.6%, and 94.4%, respectively, for the detection of RIF resis-
tance, but the same study reported sensitivity and specificity
values of 83.3% and 93.8%, respectively, for the detection of
INH resistance [16]. Studies in Uganda and France [17,18]
reported sensitivity of 100% for the detection of RIF
resistance.
In this study, the GenoType MTBDRplus assay identified
RIF-resistance-specific mutation by rpoB MUT probes, which
was detected in five of the nine RIF-resistant isolates. Higher
specific mutation on the rpoB gene was reported in another
study in India [19] and in South Africa [20].
The result of this study showed that of the five specific
mutations of the rpoB gene, three had mutations at Codon
S531L. The remaining 22.2% (2/9) had mutation at Codon
H526D. A similar finding was reported by a study conducted
in India [21]. In four of the nine RIF-resistant isolates, WT8
probe was missing with no gain in MUT3 probes, which indi-
cated the presence of a less common or rare mutation.
Similarly, RIF-resistant isolates with the missing of WT8
probe without any MUT band were reported in other studies
from New Delhi, France and Vietnam [16,18,22]. Another
study conducted in northwest Ethiopia reported that all phe-
notypically defined RIF-resistant strains and MDR strains had
mutations conferring resistance to RIF and INH (i.e., MDR).
In this study, the frequency of mutation at Codon S531L
occurred more in two of the three MDR strains and in one
of the six RIF mono-resistant strains. However, higher fre-
quency of mutation at Codon S531L was reported from India
and South Africa in MDR and RIF mono-resistant strains
[16,20].
In the GenoType MTBDRplus assay, resistance to INH is
detected by probes of the katG and inhA genes. The higher fre-
quency of resistance to INH occurred due to mutation of the
katG gene, whereas lower frequency of resistance was caused
by the mutations in the promoter region of the inhA gene [23].
Of the 25 INH-resistant isolates, katG mutation occurred in
88% (22/25) of the isolates. In all of these 22 isolates, specific
mutations were found at Codon S315T1 of the katG gene,
which was also reported by other studies conducted in north-
west Ethiopia [15] and India [19]. Some studies reported lower
frequencies of mutation in the katG gene at Codon S315T1
from Uganda, France, and South Africa [17,18,20].
Mutations in the inhA gene occurred in only three of the 25
INH-resistant isolates, which is similar to the frequency of
inhA mutation reported from the northwest part of Ethiopia
[15]. Compared with these findings, a study from North India
reported the occurrence of low frequency of INH-resistance
mutation in the inhA gene [19]. In contrast to these findings,
higher inhA gene mutation was reported from Tunisia [24]
and Canada [25]. Specific inhA mutations were found in twoof the three INH-resistant isolates, which had mutation in
Codon C15T, but in the remaining one isolate, the inhA WT2
gene was missing without the presence of a specific mutation
band. In this study, four of the phenotypically defined INH-
resistant strains had nomutations in the katG and inhA genes.
This could suggest that there may be other mutations in other
codons of the katG and inhA genes or the presence of some
unidentified mutations in other genomic regions such as
ahpC, kasA, and furA.
In conclusion, the findings of this study revealed that the
GenoType MTBDRplus assay has high sensitivities and
specificities for detecting RIF- and INH-resistant, and MDR
M. tuberculosis isolates, suggesting the potential role of this
assay for the control of TB in Ethiopia and other countries.Conflicts of interest
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